荷兰-比利时肝转移立体定向放疗登记研究:515例患者与668个转移灶的临床结局
该多中心登记研究纳入13家中心(荷兰12家、比利时1家)按共同协议治疗的515例肝转移患者、668个转移灶,中位年龄71岁,最常见原发为结直肠癌(80.3%)。中位随访1.1年(局部控制)和2.3年(生存),1年局部控制率87%、总生存率84%,≥3级毒性3.9%。
要点
- 肝转移SBRT后1年局部控制率87%、1年总生存率84%。
- ≥3级毒性发生率为3.9%,安全性可接受。
- 最常用分割方案为3×18-20 Gy(36.0%)。
核心结论
- 该多中心大样本研究证实肝转移SBRT局部控制率高、毒性有限,应作为肝转移多学科治疗的重要组成部分。
研究设计与样本
- 由13家中心(荷兰12家、比利时1家)建立共享网络登记库,各中心预先统一收集条目、分割方案及危及器官约束。
- 2013年1月1日至2019年7月31日共登记515例患者、668个肝转移灶,仅单独作为独立靶区治疗且至少1次影像随访的447个病灶纳入局部控制分析。
- ≥3级毒性按Common Terminology Criteria of Adverse Events(v4.03)评定。
主要发现
- 患者中位年龄71岁,最常见原发肿瘤为结直肠癌(80.3%),其次为肺癌(8.9%)和乳腺癌(4%)。
- 局部控制分析的中位随访时间为1.1年,生存分析为2.3年。
- 1年局部控制率为87%,1年总生存率为84%。
- ≥3级毒性见于3.9%的患者。
关键数值与推荐
- 最常用分割方案为3×18-20 Gy(36.0%),其次为8×7.5 Gy(31.8%)、5×11-12 Gy(25.5%)和12×5 Gy(6.7%)。
- 局部控制分析仅纳入单独作为独立靶区治疗且至少1次影像随访的肝转移灶,共447个。
临床怎么用
- 肝转移SBRT可参照本登记研究采用的分割方案与危及器官约束实施,预期可获得高局部控制与低毒性。
- 应将SBRT纳入肝转移多学科综合治疗路径。
局限性
- 随访由各中心自行决定,非统一计划随访。
- 局部控制分析仅纳入447个病灶,且要求至少1次影像随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although various studies have reported that stereotactic body radiation therapy (SBRT) for liver metastases has high local control rates and relatively low toxicity, most series included a small number of patients. We aimed to validate these outcomes in a large multi-institution patient cohort treated in accordance with a common protocol. METHODS AND MATERIALS: A shared web-based registry of patients with liver metastases treated with SBRT was developed by 13 centers (12 in the Netherlands and 1 in Belgium). All the centers had previously agreed on the items to be collected, the fractionation schemes, and the organs-at-risk constraints to be applied. Follow-up was performed at the discretion of the centers. Patient, tumor, and treatment characteristics were entered in the registry. Only liver metastases treated individually as independent targets and with at least 1 radiologic follow-up examination were considered for local control analysis. Toxicity of grade 3 or greater was scored according to the Common Terminology Criteria of Adverse Events (v4.03). RESULTS: Between January 1, 2013, and July 31, 2019, a total of 515 patients were entered in the web-based registry. The median age was 71 years. In total, 668 liver metastases were registered, and 447 were included for local control analysis. The most common primary tumor origin was colorectal cancer (80.3%), followed by lung cancer (8.9%) and breast cancer (4%). The most-used fractionation scheme was 3x18-20 Gy (36.0%), followed by 8x7.5 Gy (31.8%), 5x11-12 Gy (25.5%), and 12x5 Gy (6.7%). The median follow-up time was 1.1 years for local control and 2.3 years for survival. Actuarial 1-year local control was 87%; 1-year overall survival was 84%. Toxicity of grade 3 or greater was found in 3.9% of the patients. CONCLUSIONS: This multi-institutional study confirms the high rates of local control and limited toxicity in a large patient cohort. Stereotactic body radiation therapy should be considered a valuable part of the multidisciplinary approach to treating liver metastases.
引用
- Méndez Romero A, Schillemans W, van Os R, et al. The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. Int J Radiat Oncol Biol Phys. 2021. PMID: 33451857. doi:10.1016/j.ijrobp.2020.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。